1
|
Bernardino TC, Astray RM, Pereira CA, Boldorini VL, Antoniazzi MM, Jared SGS, Núñez EGF, Jorge SAC. Production of Rabies VLPs in Insect Cells by Two Monocistronic Baculoviruses Approach. Mol Biotechnol 2021; 63:1068-1080. [PMID: 34228257 DOI: 10.1007/s12033-021-00366-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 06/28/2021] [Indexed: 12/12/2022]
Abstract
Rabies is an ancient zoonotic disease that still causes the death of over 59,000 people worldwide each year. The rabies lyssavirus encodes five proteins, including the envelope glycoprotein and the matrix protein. RVGP is the only protein exposed on the surface of viral particle, and it can induce immune response with neutralizing antibody formation. RVM has the ability to assist with production process of virus-like particles. VLPs were produced in recombinant baculovirus system. In this work, two recombinant baculoviruses carrying the RVGP and RVM genes were constructed. From the infection and coinfection assays, we standardized the best multiplicity of infection and the best harvest time. Cell supernatants were collected, concentrated, and purified by sucrose gradient. Each step was used for protein detection through immunoassays. Sucrose gradient analysis enabled to verify the separation of VLPs from rBV. Through the negative contrast technique, we visualized structures resembling rabies VLPs produced in insect cells and rBV in the different fractions of the sucrose gradient. Using ELISA to measure total RVGP, the recovery efficiency of VLPs at each stage of the purification process was verified. Thus, these results encourage further studies to confirm whether rabies VLPs are a promising candidate for a veterinary rabies vaccine.
Collapse
Affiliation(s)
- Thaissa Consoni Bernardino
- Laboratório de Biotecnologia Viral, Instituto Butantan, Av Vital Brasil 1500, São Paulo, CEP, 05503-900, Brazil
| | - Renato Mancini Astray
- Laboratório de Biotecnologia Viral, Instituto Butantan, Av Vital Brasil 1500, São Paulo, CEP, 05503-900, Brazil
| | - Carlos Augusto Pereira
- Laboratório de Biotecnologia Viral, Instituto Butantan, Av Vital Brasil 1500, São Paulo, CEP, 05503-900, Brazil
| | - Vera Lucia Boldorini
- Laboratório de Biotecnologia Viral, Instituto Butantan, Av Vital Brasil 1500, São Paulo, CEP, 05503-900, Brazil
| | | | | | - Eutimio Gustavo Fernández Núñez
- Grupo de Engenharia de Bioprocessos. Escola de Artes, Ciências E Humanidades (EACH), Universidade de São Paulo, São Paulo, SP, Brazil
| | - Soraia Attie Calil Jorge
- Laboratório de Biotecnologia Viral, Instituto Butantan, Av Vital Brasil 1500, São Paulo, CEP, 05503-900, Brazil.
| |
Collapse
|
2
|
Zayed H. Vaccine Development Against COVID-19 Prior to Pandemic Outbreaks, Using in vitro Evolution and Reverse Genetics. Front Immunol 2020; 11:2051. [PMID: 32922408 PMCID: PMC7456802 DOI: 10.3389/fimmu.2020.02051] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 07/28/2020] [Indexed: 12/01/2022] Open
Affiliation(s)
- Hatem Zayed
- Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
| |
Collapse
|
3
|
Affiliation(s)
- Xianxun Sun
- State Key Laboratory of VirologyWuhan Institute of VirologyCenter for Biosafety Mega‐ScienceChinese Academy of Sciences Wuhan 430071 China
- College of Life ScienceJiang Han University Wuhan 430056 China
| | - Zongqiang Cui
- State Key Laboratory of VirologyWuhan Institute of VirologyCenter for Biosafety Mega‐ScienceChinese Academy of Sciences Wuhan 430071 China
| |
Collapse
|
4
|
Lai CC, Cheng YC, Chen PW, Lin TH, Tzeng TT, Lu CC, Lee MS, Hu AYC. Process development for pandemic influenza VLP vaccine production using a baculovirus expression system. J Biol Eng 2019; 13:78. [PMID: 31666806 PMCID: PMC6813129 DOI: 10.1186/s13036-019-0206-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 09/06/2019] [Indexed: 02/06/2023] Open
Abstract
Background Influenza viruses cause hundreds of thousands of respiratory diseases worldwide each year, and vaccination is considered the most effective approach for preventing influenza annual epidemics or pandemics. Since 1950, chicken embryonated eggs have been used as the main method for producing seasonal influenza vaccines. However, this platform has the main drawback of a lack of scale-up flexibility, and thus, egg-based vaccine manufacturers cannot supply sufficient doses within a short period for use for pandemic prevention. As a result, strategies for reducing the manufacturing time and increasing production capacity are urgently needed. Non-virion vaccine methods have been considered an alternative strategy against an influenza pandemic, and the purpose of maintaining an immunogenic capsule structure with infectious properties appears to be met by the virus-like particle (VLP) platform. Results An influenza H7N9-TW VLP production platform using insect cells, which included the expression of hemagglutinin (HA), NA, and M1 proteins, was established. To scale up H7N9-TW VLP production, several culture conditions were optimized to obtain a higher production yield. A high level of dissolved oxygen (DO) could be critical to H7N9-TW VLP production. If the DO was maintained at a high level, the HA titer obtained in the spinner flask system with ventilation was similar to that obtained in a shake flask. In this study, the HA titer in a 5-L bioreactor with a well-controlled DO level was substantially improved by 128-fold (from 4 HA units (HAU)/50 μL to 512 HAU/50 μL). Conclusions In this study, a multigene expression platform and an effective upstream process were developed. Notably, a high H7N9-TW VLP yield was achieved using a two-step production strategy while a high DO level was maintained. The upstream process, which resulted in high VLP titers, could be further used for large-scale influenza VLP vaccine production.
Collapse
Affiliation(s)
- Chia-Chun Lai
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan.,2College of Life Science, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsinchu, 30013 Taiwan
| | - Yu-Chieh Cheng
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan
| | - Pin-Wen Chen
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan
| | - Ting-Hui Lin
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan.,2College of Life Science, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsinchu, 30013 Taiwan
| | - Tsai-Teng Tzeng
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan
| | - Chia-Chun Lu
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan
| | - Min-Shi Lee
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan
| | - Alan Yung-Chih Hu
- National Institute of Infectious Diseases and Vaccinology, NHRI, 35 Keyan Road, Zhunan, Miaoli County, 35053 Taiwan
| |
Collapse
|
5
|
Chaves LCS, Ribeiro BM, Blissard GW. Production of GP64-free virus-like particles from baculovirus-infected insect cells. J Gen Virol 2018; 99:265-274. [DOI: 10.1099/jgv.0.001002] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Affiliation(s)
- Lorena C. S. Chaves
- Cell Biology Department, Institute of Biology, University of Brasilia, Brasilia, DF, Brazil
- Boyce Thompson Institute at Cornell University, Ithaca, NY, USA
| | - Bergmann M. Ribeiro
- Cell Biology Department, Institute of Biology, University of Brasilia, Brasilia, DF, Brazil
| | | |
Collapse
|
6
|
Kim HJ, Kim HJ. Current status and future prospects for human papillomavirus vaccines. Arch Pharm Res 2017; 40:1050-1063. [PMID: 28875439 DOI: 10.1007/s12272-017-0952-8] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 08/24/2017] [Indexed: 01/08/2023]
Abstract
Cervical cancer is the fourth most frequent cancer among women worldwide. Human papillomaviruses (HPVs) cause almost all cervical cancers in low-income countries. Three prophylactic HPV virus-like particle-based vaccines have been licensed to date, and they have all shown high efficacy and reliable safety profiles. However, isolated safety issues have resulted in a reluctance to use these vaccinations. In addition, the high prices of the vaccinations have caused the inequitable distribution of the vaccine: the prices are unaffordable for low-income countries. Meanwhile, great effort has been put into the development of therapeutic HPV vaccines, including protein/peptide-, live vector-, DNA- and cell-based vaccines. These new vaccines have considerable therapeutic potential but limited practical use. The development of immune checkpoint inhibitors and personalized immunotherapy remain challenges for future study. In this article, the current status of the licensed vaccines, therapeutic HPV vaccines and biosimilars, and new platforms for HPV vaccines, are reviewed, and safety issues related to the licensed vaccines are discussed. In addition, the prospects for HPV vaccines are considered.
Collapse
Affiliation(s)
- Hyoung Jin Kim
- Laboratory of Virology, College of Pharmacy, Chung-Ang University, 84 Heukseok-Ro, Dongjak-Gu, Seoul, 06974, South Korea
| | - Hong-Jin Kim
- Laboratory of Virology, College of Pharmacy, Chung-Ang University, 84 Heukseok-Ro, Dongjak-Gu, Seoul, 06974, South Korea.
| |
Collapse
|
7
|
Kotin RM, Snyder RO. Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines. Hum Gene Ther 2017; 28:350-360. [DOI: 10.1089/hum.2017.042] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Robert M. Kotin
- Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts
| | | |
Collapse
|